- $1.56bn
- $1.29bn
- $16.10m
Acting US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms
Replimune jumps after US FDA Commissioner Makary resigns
uniQure, Replimune climbs after FDA Commissioner Makary resigns
Replimune, uniQure rise; FDA commissioner Makary plans to resign
Replimune, uniQure rise after report FDA chief Makary may be ousted
Netherlands' uniQure Q1 revenue misses estimates
US FDA taps Szarama as acting head of vaccine unit (updated)
US FDA taps Szarama as acting head of vaccine unit, Politico reports
uniQure plans to submit UK application for Huntington's disease therapy, shares up
FDA's Makary expects decision on Prasad successor in coming weeks (updated)
Rare disease advocacy group urges Trump administration to restore FDA clarity
Live Markets: Prasad's exit a win for biotechs, but don't celebrate yet
Biotechs gain as FDA vaccines chief's exit seen as easing regulatory pathway
Uniqure jumps after FDA vaccines chief Vinay Prasad to step down
FDA vaccines chief Vinay Prasad to step down in April (updated)
UniQure pushes back on FDA's criticism of Huntington’s therapy; shares up
Sr. FDA official calls uniQure's Huntington's disease treatment a failure (updated)